HOUSTON, TX / ACCESS Newswire / September 2, 2025 / Epique Realty is proud to announce that its CEO and Co-Founder, Joshua Miller, has been named a 2025 HousingWire Vanguard. This prestigious award recognizes the most influential C-level executives in the housing economy who are moving markets forward with vision, resilience, and unmistakable impact.
The Vanguard award celebrates leaders who have turned obstacles into opportunities, and Miller was selected for his revolutionary work in fundamentally challenging and reshaping the traditional real estate brokerage model.
“The 2025 HousingWire Vanguards exemplify what it means to lead with vision and resilience,” said Sarah Wheeler, Editor-in-Chief of HousingWire. “These leaders aren’t just driving growth within their organizations; they’re shaping the future of housing itself. Their achievements reflect the innovation, adaptability, and commitment required to thrive in today’s rapidly evolving market.”
Miller’s co-founders celebrated the honor as a testament to his unique leadership style.
“From day one, Josh has led with a vision that many thought was impossible, but he saw it with perfect clarity,” said Janice Delcid, CFO and Co-Founder. “As a Co-Founder and CFO, I’ve had a front-row seat to his leadership, blending bold, disruptive innovation with a deep sense of compassion. This Vanguard award is a well-deserved recognition of a leader who truly puts people and purpose first.”
“Josh dreams bigger than anyone I know, and then he inspires our entire team to work together and build that dream into a reality,” said Christopher Miller, COO and Co-Founder. “Operationally, scaling our vision for a tech-forward, agent-centric brokerage was a monumental task, but his vision and inspiration made it achievable, We are incredibly proud to see him recognized.”
Miller’s win is a direct result of his innovative work developing the #1-ranked Epique.ai platform and creating an agent-first financial model that democratizes technology and provides over 75 unheard-of free benefits from healthcare to transaction coordination. This model ignited the firm’s historic growth from a Texas startup into a 50-state powerhouse with over 4,000 agents and more than $4.2 billion in annual sales volume.
“To be named a Vanguard by HousingWire is an incredible honor that I share completely with my co-founders, Janice and Chris, and our entire Epique family,” said Joshua Miller. “This award isn’t for one person; it’s a validation of our collective mission to build a more supportive and equitable future for real estate professionals. Our agents are the real vanguards out in the field every day, and I am deeply proud to serve them.”
About Epique Realty Shaping the future of housing, Epique Realty is one of the fastest-growing real estate brokers. Epique now operates in all fifty states with over 4,000 agents and global expansion underway. Its revolutionary agent-first model provides unheard of free extensive benefits with award-winning AI and a culture of radical generosity. By questioning industry norms and putting agents at the center of its universe, Epique is transforming and defining the future of real estate.#BeEpique
CFO and Mother of Seven Recognized for Driving Transformative Impact and Change in Real Estate
HOUSTON, TX / ACCESS Newswire / September 2, 2025 / Epique Realty is beyond proud to announce that its very own Chief Financial Officer and Co-Founder, Janice Delcid, has been named a winner of the prestigious 2025 Global Women of Influence Award. Selected from a competitive and multidisciplinary field of applicants worldwide, this award celebrates extraordinary women who have demonstrated exceptional leadership and made a transformative impact on society.
Janice Delcid was recognized for shattering industry barriers by co-founding one of the first national woman-owned brokerages in history and for architecting the company’s revolutionary “radical generosity” financial model. Her fellow co-founders celebrated her as the heart and soul of Epique’s success.
“I could not ask for a better partner in this journey,” said Joshua Miller, CEO and Co-Founder. “Janice is an excellent financial architect who has proven that a business model rooted in generosity can be wildly successful. She is a force for good, and this award honors the profound impact she has on our company and on every person and community she touches.”
“Janice is the cultural cornerstone of Epique,” said Christopher Miller, COO and Co-Founder. “She ensures that every decision we make is guided by compassion, integrity, and a genuine desire to uplift others. She is more than a CFO. She is a visionary, a mentor, and a humanitarian who has proven that a woman of influence doesn’t just build a successful company, she builds a better, more compassionate world along with it. This global recognition is a perfect tribute to the incredible family she has built within our company.”
As CFO, Janice has helped steer Epique’s growth from a regional startup to a 50-state powerhouse with over 4,000 agents. Beyond her financial acumen, she has spearheaded the company’s philanthropic initiatives, including a drive to deliver 10,000 backpacks to children in need and the creation of NEMO, an agent-led disaster relief organization. She also championed another new program, Epique Cares, a non-profit initiative where contributions are made from the heart, without tax incentives, purely to support those in need.
“I am deeply humbled and grateful to receive this incredible honor alongside so many inspiring women,” said Janice Delcid. “To me, this award is a celebration of what’s possible when you lead with both your head and your heart. I share this recognition with my entire Epique family and hope that it inspires other women to build their own tables and lead with purpose.”
About Epique Realty Shaping the future of housing, Epique Realty is one of the fastest-growing real estate brokers. Epique now operates in all fifty states with over 4,000 agents and global expansion underway. Its revolutionary agent-first model provides unheard of free extensive benefits with award-winning AI and a culture of radical generosity. By questioning industry norms and putting agents at the center of its universe, Epique is transforming and defining the future of real estate.#BeEpique
The UK’s fastest-growing medicinal cannabis clinic begins international strategy with further online investment.
NOTTINGHAM, ENGLAND / ACCESS Newswire / September 2, 2025 / Releaf, the UK’s fastest-growing medicinal cannabis clinic, has acquired the domain Releaf.com for £110,000 as part of its global expansion strategy. The move comes as the company overtakes £2.1 million in monthly revenue and prepares to take its proven healthcare model to international markets.
Releaf’s technology platform, fully integrated with the NHS Spine, now serves over 300,000 unique website visitors monthly. The platform uses AI-assisted triage to match patients with specialist prescribers and delivers doctor-led care directly to patients’ doors, effectively removing traditional barriers to access.
Jon Dunn, Marketing Director at Releaf, explains, “Releaf.com is our launchpad for global growth. This isn’t just a domain, it’s our passport to every market we enter. It gives us instant credibility, makes our brand unforgettable, and ensures patients worldwide know exactly where to find us.”
The company has achieved significant growth in the UK market, onboarding over 120 new patients daily and conducting more than 300 consultations each day. This momentum is driving substantial expansion, with plans to double clinical operations month-on-month to reach over 6,000 initial consultation slots per month by year end.
Having demonstrated its approach works in the UK’s highly regulated healthcare environment, Releaf is now positioning its technology-led model for international rollout. The company is targeting markets where patients face similar structural challenges in accessing cannabinoid healthcare.
Releaf continues to reinvest into clinician onboarding, patient support, and platform enhancements, ensuring high standards of care while building capacity for international expansion. With European operations already underway, the company is well-positioned to become a leading provider of regulated cannabinoid healthcare globally.
About Releaf
Launched in 2024, Releaf Dispensary Ltd the UK’s fastest-growing and most-trusted* medical cannabis clinic, serving patients through its advanced healthtech platform. With a prescriber network of over 40 specialists, we deliver evidence-based cannabinoid care directly to patients’ homes through tailored treatment plans.Fully integrated with NHS systems, Releaf has transformed access to medicinal cannabis treatment in the UK and is now expanding internationally. *According to Trustpilot.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Duluth, Georgia – September 02, 2025 – (PRESS ADVANTAGE) –
Arrowhead Clinic in Duluth, Georgia, has launched a new healthcare program aimed at helping car accident victims right after they get hurt. The focus is on giving them the care they need within the first 24 hours after an accident. This time frame is important because it can prevent injuries from getting worse. The updated services are now designed to make post-accident care faster and easier, and the clinic is ready to welcome walk-in patients who need urgent help.
The clinic offers quick medical check-ups, detailed injury reports, diagnostics using advanced testing methods, and same-day chiropractic appointments for those feeling pain after an accident. They have also prepared a guide to help accident victims through what needs to be done in those first 24 hours. The guide covers keeping safe, contacting emergency services, and setting up needed same day evaluations.
Dr. Darris Gentry, DC, from Arrowhead Clinic shared why this is so important. “Our goal is to give quick and effective care to our patients who have been in an auto accident,” he said. “It’s not just about treatment; it’s also about education and support during those important first 24 hours.” Through this effort, Arrowhead Clinic aims to help patients manage their health needs and navigate any legal issues following an accident.
Not only do they provide urgent medical assessments, but they also offer a complete recovery plan. This includes careful tracking of symptoms, coordination with other healthcare providers and legal consultants, and the use of advanced tools to find the exact cause of pain or injury. Their all-around approach makes sure that patients receive comprehensive care.
An Arrowhead Clinic in Duluth review praised the clinic for its commitment. The reviewer appreciated the attentive and well-organized staff. They noted that the clinic handled her case efficiently, offering valuable support and information which helped her manage her first accident experience better. Such positive feedback shows the clinic’s dedication to delivering high-quality care and ensuring a good experience for patients.
Arrowhead Clinic also supports patients beyond just health services. They offer referrals to personal injury attorneys to help patients deal with legal matters and reduce the financial stress that accidents often bring. The clinic provides specialized treatments, including for whiplash and other musculoskeletal issues resulting from truck, car, and motorcycle accidents, along with a range of other injuries from sports, work, and slip and fall incidents. Arrowhead Clinic has been offering chiropractic care for injury victims for over 48 years and continuously updates its methods to keep up with modern practices. This ensures that patients get access to the newest and most efficient treatments.
Dr. Gentry emphasized the clinic’s broad services for car accident victims. “Our clinic is dedicated to combining expert chiropractic treatment with a caring approach,” he noted. He pointed out that their consistent effort to assist first-time patients and guide them through every recovery stage is what makes the clinic unique.
For those looking for auto accident treatment from Arrowhead Clinic in Duluth, the clinic’s new initiative focuses on quick responses and personalized care for each case. This aims to support patients during difficult times, helping with physical recovery and giving peace of mind.
Arrowhead Clinic in Duluth is open every week and provides same-day appointments and walk-in services. This highlights their commitment to being easily accessible for everyone needing immediate care. With a focus on patient comfort and understanding, Arrowhead Clinic ensures that people involved in auto accidents receive comprehensive care that promotes healing and recovery As a recognized Arrowhead Clinic Chiropractor in Duluth GA, the clinic is committed to maintaining its reputation by constantly enhancing treatment services and patient care..
Patients can also benefit from various resources available through Arrowhead Clinic, including a chiropractic blog, a car accident guide, a chiropractic care guide, and wellness options. Arrowhead Clinic invites those who need care to visit their website or visit them directly.
###
For more information about Arrowhead Clinic – Duluth, contact the company here:
Arrowhead Clinic – Duluth Dr. Darris Gentry, DC (770) 525-1431 info@arrowheadclinics.com 2131 Pleasant Hill Rd #122, Duluth, GA 30096
ATLANTA, GA / ACCESS Newswire / September 2, 2025 / Ahead of its premier life science event advancing Clinical Trial technology and innovation, Research Revolution, Florence Healthcare today announced its upcoming AI-centric workflows aimed at transforming clinical trials conducted across the study life-cycle. These solutions will significantly accelerate and enhance site identification, feasibility, start up, study conduct and remote monitoring for both sites and sponsors.
Built in collaboration with top sponsors, CRO partners, and hundreds of research sites; these new Human-in-loop (HITL) AI capabilities are built to supercharge clinical trial professionals as they tackle some of the most persistent challenges in the industry:
Limited Visibility Into Site Performance: Sponsors struggle to identify the right research sites, relying on disparate and stagnant data sources that provide limited visibility into true site capacity and performance.
Inefficient Study Start-Up Processes: Timelines are bogged down by manual and fragmented workflows and communication across stakeholders. Meaning critical data and documents are trapped in email chains, portals, and spreadsheets- causing version control issues, compliance risks, and inefficiencies.
Fragmented Oversight & Monitoring: Fragmented data and documents means that sponsor oversight is limited. Disparate systems prevent monitors from having real-time visibility into trial progress. As a consequence, costly physical site visits are still needed.
AI Assisted workflows will be available to Sponsors, CROs and Research Sites in October 2025
Florence Healthcare will introduce modules to directly address the challenges listed above. These will include:
Site Identification & Feasibility: Utilizing these new workflows, Sponsors will be able to quickly search across site profiles according to therapeutic area, geography, and real-time performance criteria to pick the right sites for study startup. From there they can deliver protocol-specific feasibility surveys, focusing on questions that are informative rather than repetitive. Sites will then be able to leverage an AI-driven workflow to accelerate survey completion with context-specific responses highlighting Site qualifications for the specific study.
Study Start-Up: New AI-driven contract negotiations will accelerate time to startup, in compliance with Site and Sponsor guidelines for contracts. In addition, a fully automated document exchange with Site eISF will provide the flexibility to tailor documents to specific Site networks or regions. The enhanced AI workflows will also simplify document management across startup and trial conduct, reducing administrative work for sites and sponsors.
Remote Monitoring: Remote Monitoring will also receive an AI upgrade. New reports providing deeper insights into Study progress across Sites or at specific sites will be available, allowing for quick intervention and remediation to keep trials on track, and obviating the need for physical site visits.
These AI-centric product workflows will enter limited availability in October 2025 for early adopters. These workflows are built on Florence’s validated and GxP-compliant infrastructure-trusted by over 37,000 research sites globally. They include full audit traceability, 21 CFR Part 11 support, and interoperability APIs for CTMS, eTMF, and identity systems.
“We’re not just automating the trial conduct for speed,” said Shankar Jagannathan, COO at Florence. “We’re creating a shared, AI-augmented experience between sponsors and sites to reduce manual work and increasing capacity, while minimizing risk -one that’s more intelligent, scalable, and efficient.”
About Florence Healthcare
Florence is a purpose-built platform that connects sponsors and sites to accelerate clinical trials, improve operational capacity, and reduce risk. Designed for scale, Florence streamlines workflows, enhances collaboration, and delivers real-time visibility across studies-empowering research teams to move faster, stay inspection-ready, and increase trial throughput with fewer resources.
Dateline to Engage US Securities Counsel and Auditing Firm to Initiate SEC Registration and Reporting Compliance
SYDNEY, AU / ACCESS Newswire / September 2, 2025 / Dateline Resources Limited (OTCQB:DTREF)(ASX:DTR) (“Dateline” or the “Company”), a leading explorer and developer of high-value mineral assets, announces the completion of a $25 million institutional placement, reflecting strong investor confidence in the Company’s strategic direction and the potential of its flagship Colosseum Gold and Rare Earth Elements (REE) Project in San Bernardino County, California. The issue was heavily oversubscribed and was conducted at an issue price of $0.215 per share, resulting in the issuance of 116,279,070 new ordinary shares. The Placement was completed under the Company’s existing placement capacity pursuant to ASX Listing Rule 7.1. Shaw and Partners acted as lead manager and bookrunner to the placement. Following the placement, the Company’s total cash position has increased to over $35 million.
In addition, Dateline has commenced the selection of a U.S. legal and an auditing firm to assist in the registration process with the U.S. Securities and Exchange Commission (SEC). This initiative will ensure Dateline’s financial statements and disclosures are fully compliant with SEC reporting standards. These strategic steps are designed to enhance Dateline’s visibility and accessibility to US investors, particularly as interest in the Colosseum Project grows amid increasing demand for domestic sources of critical minerals.
This capital infusion will enable Dateline to expedite its drilling programs, building on recent geophysical surveys and geochemical results that have revealed significantly greater resource potential at Colosseum than initially anticipated. The funds will support the parallel advancement of both the gold and REE initiatives, positioning the Company to achieve production milestones at an accelerated pace. Proceeds from the Placement will be used to ramp up exploration and development at the Colosseum Gold and Rare Earth Elements (REE) Project in California. The new capital will enable the deployment of additional drill rigs to test the highest-priority targets, accelerating the timeline for resource growth and development. The Company is prioritizing early site works and long lead-time equipment orders (as part of the ongoing Bankable Feasibility Study) to fast-track the reopening of the Colosseum mine. Funds will also be applied toward general working capital and further business development opportunities as needed.
Recent exploration highlights include the integration of a 3D magneto-telluric (MT) geophysical survey with detailed gravity data, leading to the identification of six new high-priority breccia pipe targets. These targets exhibit coincident geophysical anomalies, gravity lows and resistivity lows, similar to the known gold-bearing breccia pipes at Colosseum, which host the existing 1.1-million-ounce gold Mineral Resource Estimate (MRE) of 27.1Mt @ 1.26g/t Au, with over 67% in Measured and Indicated categories. Four of these new anomalies are comparable in scale or larger than those associated with the known pipes, and the MT results indicate the known structures extend to at least ~300 metres below prior drilling, suggesting substantial depth potential.
In parallel, the 3D MT inversion has confirmed multiple high-priority REE drilling targets, including a prominent 2200N anomaly, a strong resistive feature extending from depth to surface, coincident with outcropping fenite dykes. This anomaly aligns with a relative gravity high and subdued magnetic response, characteristic of carbonatite-related REE systems similar to the nearby Mountain Pass mine. Deep resistivity structures have been identified beneath all mapped fenite outcrops, demonstrating consistency in the survey results and reinforcing the REE potential. Geochemical sampling from felsite outcrops has further confirmed gold-pathfinder elements coincident with gravity lows, enhancing confidence in these targets.
U.S. Government Recognition and Support
Dateline’s progress is further reinforced by strong support from the US government. In letters dated August 26, 2025, Secretary of the Interior Doug Burgum reaffirmed the validity of the Company’s existing rights at Colosseum, emphasizing the site’s role in advancing American energy independence and mineral production. Secretary Burgum noted that geologic information indicates the mine’s potential to produce gold and extract rare earth elements critical to national security and economic priorities, aligning with Executive Orders issued following the national energy emergency declaration on January 20, 2025. This endorsement highlights the US government’s commitment to responsible development of domestic resources, providing a solid foundation for Dateline’s operations.
Building on this federal support, Dateline is continuing constructive discussions with government officials regarding potential funding and support mechanisms for Colosseum. The Company highlights that this $25 million private placement is complementary to, rather than a substitute for, ongoing pursuits of U.S. government-backed initiatives, reinforcing Colosseum’s role as a strategic contributor to America’s long-term minerals independence.
Stephen Baghdadi, CEO and Managing Director of Dateline Resources, commented: “We are encouraged by the strong support from institutional investors, which validates our strategy at the Colosseum Project. Recent geophysical work has outlined six new gold targets with the same MT signature as the known breccia pipes and confirmed high-priority REE anomalies. With this funding, we are positioned to accelerate our dual-track development and unlock the significant potential value of the Colosseum.”
Dateline Resources continues to advance its exploration and development activities with a focus on creating long-term shareholder value through innovation, efficiency, and environmental stewardship. Further updates on drilling results and project milestones will be provided in due course.
About Dateline Resources Limited
Dateline Resources Limited (ASX: DTR, OTC: DTREF) is an Australian publicly listed company focused on high-value mining and exploration in North America. Its flagship Colosseum Gold-REE Project in California’s Walker Lane Trend combines a proven gold resource with emerging rare earth potential, positioning Dateline as a leader in critical minerals and precious metals. The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.
On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.
The Colosseum is located less than 10km north of the Mountain Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of applicable securities laws. These statements relate to future events or performance, including the potential of the Colosseum Project, the benefits of U.S. government support, the company’s plans for future development, and the strategic importance of the project for U.S. critical minerals supply. Forward-looking statements are based on current expectations, estimates, and projections and are subject to risks and uncertainties that could cause actual results to differ materially. These risks include fluctuations in gold and rare earth element prices, changes in regulatory or permitting processes, geological or technical challenges, market conditions affecting capital raising, environmental or social factors, and risks related to securing government funding. Dateline Resources cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update or revise these statements, except as required by law.
Contact Information
Stephen Baghdadi Managing Director Dateline Resources Limited +61 2 9375 2353 info@datelineresources.com.au www.datelineresources.com.au
MCLEAN, VA / ACCESS Newswire / September 2, 2025 / Gladstone Alternative Income Fund (“Gladstone Alternative” or the “Fund”) announced today that its board of trustees declared monthly cash distributions to shareholders for the month of September. The September distribution amount is $0.00193 per calendar day for each issued and outstanding Class A share, Class C share, and Class I share for the period beginning September 1, 2025 and ending September 30, 2025 (for shareholders who own shares all 30 days in September, the distribution will total $0.0579 per share). The distributions will be paid on September 30, 2025 for Dividend Reinvestment Plan (“DRIP”) participants and October 1, 2025 for non-DRIP participants.
John Sateri, President of Gladstone Alternative, noted, “We are pleased to announce the seventh consecutive monthly dividend for Gladstone Alternative, continuing our commitment to delivering consistent income to our investors. We look forward to continuing to create long-term value in the months and years ahead by generating sustainable returns for our shareholders while providing them access to a diversified portfolio of private credit and equity investments.”
About Gladstone Alternative Income Fund
Gladstone Alternative Income Fund is a non-diversified, unlisted, closed-end management investment company registered under the Investment Company Act of 1940 and is operating as an interval fund. The Fund seeks to achieve and grow current income by investing primarily in directly originated loans to lower and middle market private businesses in the United States, broadly syndicated loans and commercial real estate loans.
Investors are advised to carefully consider the investment objectives, risks and charges, and expenses of Gladstone Alternative Income Fund before investing. The prospectus, dated July 29, 2025, which has been filed with the U.S. Securities and Exchange Commission, and as supplemented from time to time, contains this and other information about the Fund and should be read carefully before investing. You may get these documents for free by visiting the Fund’s website at www.gladstoneintervalfund.com or by visiting EDGAR on the SEC’s website at www.sec.gov. To obtain a copy of the prospectus, you may also contact Gladstone Securities, LLC, the dealer manager and distributor for this offering, which will arrange to send you the prospectus if you request it by calling toll-free at (833) 849-5993.
VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / 1933 Industries Inc. (the “Company” or “1933 Industries”) (CSE:TGIF)(OTCID:TGIFF), a Nevada-focused cannabis cultivator and producer, is pleased to announce that it has entered into a Debenture Repurchase Agreement (the “Agreements”) with two arm’s length parties (together the “Vendors“), for the repurchase and cancellation of a portion of Company’s outstanding unsecured convertible debentures.
Pursuant to the Agreements, the Company will repurchase $475,000 in principal value of debentures for a total cash consideration of $47,500 CAD. Upon closing, the debentures will be transferred, cancelled and removed from the Company’s outstanding liabilities.
The Agreement is being conducted in accordance with the provisions of the trust indenture dated December 31, 2023, applicable securities laws, and the policies of the Canadian Securities Exchange (the “CSE“).
The Company believes that the repurchase is in the best interest of shareholders and reflects its ongoing commitment to strengthening its balance sheet and reducing its liabilities. Following completion of the repurchase, an aggregate of $2,598,000 in principal value debentures will remain outstanding.
The closing of the repurchase is subject to customary conditions and regulatory approvals, including any required filings with the CSE, and is expected to occur on or around September 5, 2025.
About 1933 Industries Inc.
1933 Industries is a Nevada-based licensed producer, focused on the cultivation and extraction of a large portfolio of cannabis consumer products in a variety of formats under its flagship brands, Alternative Medicine Association (AMA) and Level X. Its product offerings are cultivated at the Company’s 68,000 sq. ft. indoor facility and marketed directly to retail dispensaries. AMA branded flower, infused pre-rolls, and in-house boutique concentrates consistently rank as the top products sold in Nevada. For more information, please visit www.1933industries.com
For further information please contact: Alexia Helgason, VP, Investor Relations 604-728-4407 alexia@1933industries.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. 1933 Industries undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
VIRGINIA BEACH, VIRGINIA / ACCESS Newswire / September 2, 2025 / Inspire Veterinary Partners, Inc. (Nasdaq:IVP) (“Inspire” or the “Company”), an owner and provider of pet health care services throughout the U.S., announces that the Company has received formal notification on August 26, 2025 from the Nasdaq Stock Market (“Nasdaq”) determining that the Company now complies with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders’ equity (“Equity Rule”).
On April 10, 2025, the Company received formal notification from Nasdaq citing that it was out of compliance and needed to meet the requirements set forth under Listing rules 5550 (b)(1), 5550 (b)(2), or 5550 (b)(3). Confirmation of compliance was based on the Company’s Form 8-K dated August 20, 2025.
About Inspire Veterinary Partners, Inc.
Inspire Veterinary Partners is an owner and provider of pet health care services throughout the US. As the Company expands, it expects to acquire additional veterinary hospitals, including general practice, mixed animal facilities, and critical and emergency care. For more information, please visit: www.inspirevet.com.
This press release contains forward-looking statements regarding the Company’s current expectations. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the Company’s ability to execute a definitive agreement relating to the proposed acquisition, satisfy closing conditions and otherwise complete the proposed acquisition, realize financial projections related to the proposed acquisition and complete additional acquisitions in the future. These and other risks and uncertainties are described more fully in the section captioned “Risk Factors” in the Company’s public filings made with the Securities and Exchange Commission, including its Annual Report on Form 10-K. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Flagship programme will demonstrate molecular‑level traceability from waste collection to high‑value recycled resin, advancing Singapore’s Zero Waste Masterplan and reinforcing regional circular‑economy leadership.
NEW YORK, NY AND SINGAPORE, SINGAPORE / ACCESS Newswire / September 2, 2025 / Security Matters PLC (NASDAQ:SMX; SMXWW), the pioneer of “physical‑to‑digital” supply‑chain solutions, and the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector research and development (R&D) agency, today announced a strategic collaboration to pilot a national plastic circularity platform in partnership with leading brands, producers, manufacturers, waste collectors, recyclers and retailers.
This partnership combines SMX’s chemical molecular marking technology, patented reader and blockchain-based traceability platform with A*STAR’s cutting-edge digital, advanced chemical spectroscopic detection and profiling research capabilities, creating an intelligent system to permanently mark, track and analyse plastics through their entire lifecycle-from manufacturing to recycling. By enabling every plastic item to carry a secure digital record of its origin, composition, and reuse cycles, the initiative aims to greatly enhance transparency and efficiency in recycling – supporting Singapore’s vision of a sustainable, circular economy
This multi‑year partnership will integrate SMX’s invisible molecular markers, readers and blockchain ledger with blockchain, AI, advanced chemical spectroscopic detection and material profiling research capabilities from A*STAR, creating an auditable digital twin and AI system for post‑consumer plastic flows across Singapore’s collection, sorting and recycling ecosystem.
Collaboration Highlights
Phase 1 will launch the first nationwide “digital passport” for plastics, dynamically tagging and tracing more than 5 000 tonnes of postconsumer flexible and rigid waste in real time. Semi-industrial integration starts in Q1 2026, and a full scale commercial showcase is slated for Q2 2027-deliberately timed to provide industry with a turnkey compliance pathway ahead of impending extended producer responsibility mandates, with an end-stage capacity to tag and trace more than 5,000 tonnes of post-consumer plastics annually.
The full-scale commercial tagging and tracing stage is envisioned to be powered by a coalition of global and local brands, regional retailers, resin producers, converters and recyclers – unlocking high‑value, mechanically recycled feedstock and demonstrating that true circularity is mission‑critical to economic resilience.
Strategic Value & Market Context
Singapore currently incinerates 94 % of the 957 000 tonnes of plastic it generates each year, recycling just 6 % – a costly gap that burns value as well as waste. If only one-third of that stream were captured in an SMX-verified loop, the nation would avoid roughly S$27 million in annual incineration fees and create a further S$75 million in saleable, certified post-consumer resin (PCR) – a compliance dividend worth more than S$100 million every year.
The partnership between SMX and A*STAR is designed to flip that equation at scale. By embedding chemical molecular “barcodes” in every pellet and logging each hand-off on blockchain, the partners aim to lift regional recycling rates by more than 30 % and halve landfill or ash-fill volumes by 2030. When replicated across ASEAN, the same architecture unlocks an addressable market of ≈ S$4.2 billion a year in certified recycled material and platform fees – turning waste into a bankable commodity.
Plastic Cycle Token – Turning Data into Value
Each SMX-verified kilogram of recycled plastic will also be wrapped in a Plastic Cycle Token (PCT), a tradeable digital asset backed one-for-one by the molecular marker and its on-chain audit trail. The Plastic Cycle Token (PCT) is engineered to supersede traditional carbon credits – enabling recyclers to monetise verified recycled output, brands to hedge compliance risk, and investors to back measurable circularity
Demand signals are loud and cross-sectoral. FMCG, food-grade packaging, electronics and automotive brands across China, India, Indonesia, Japan and Singapore are already specifying minimum-PCR thresholds and treating traceability as insurance against compliance shocks and brand-equity risk. In markets with real enforcement, verified PCR now commands a 5-15 % premium over virgin polymer, a spread expected to widen as Extended Producer Responsibility (EPR) schemes tighten.
Against that backdrop, Phase 1 of the collaboration will create a nationwide digital passport for plastics, tagging and tracing thousands of tonnes of flexible and rigid waste in real time. The data stream will give producers a turnkey path to comply with Singapore’s Mandatory Packaging Reporting rules and forthcoming recycled-content mandates, while supplying recyclers with higher-value, mechanically recycled feedstock. In short, true circularity is no longer a nice-to-have – it is mission-critical to economic resilience and regional competitiveness.
Haggai Alon, Founder & CEO, SMX: “As Singapore marks 60 years of independence, it continues to prove that long-range planning, turns constraints into catalysts for growth.
Together with A*STAR and our industry partners, we are building a bridge from Semakauto Jurong Island – transforming what was once a disposal endpoint into a high-value feedstock stream. This programme adds a new layer to Singapore’s leadership in technology and sustainability and places a powerful tool in the region’s master toolbox as Asia drives global growth.
True circularity is driven by smart execution and adaptability. This is the first stage of a long-term plan-anchored by molecular traceability that converts waste into a verified commodity, and through the Plastic Cycle Token, a market instrument engineered to supersede traditional carbon credits with something measurable, auditable and economically useful.”
Professor Lim Keng Hui, Assistant Chief Executive Officer of the Science & Engineering Research Council, A*STAR: “This collaboration exemplifies A*STAR’s mission to translate cutting‑edge research into impactful, sustainable solutions. Together with SMX, we will harness science and engineering to close the plastics loop and strengthen Singapore’s position as a global circularity hub.”
As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.
Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.
